91高清自产国产拍,无码免费A级毛片大全,日本欧美国产中文字幕,99re热视频这里只有精品视频首页

首页

400-620-6333

提交您使用阿拉丁产品的研究文章，就得100元奖励！立即访问我们的提交页面.

跳到内容

语言

切换导航

我的购物车

搜索

菜单

账号

设置

语言

首页
应用
药物靶标
激酶
TK：酪氨酸激酶
Ramucirumab (anti-VEGFR2)

Ramucirumab (anti-VEGFR2)

规格或纯度: Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

种属反应性: Cynomolgus,Human
亚型: Human IgG1

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货
R411995-1mg	1mg	期货
R411995-5mg	5mg	期货
R411995-10mg	10mg	期货

查看相关系列

kinase insert domain receptor Antibody

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本信息

产品名称	Ramucirumab (anti-VEGFR2)
规格或纯度	Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
特异性	VEGFR2
应用	ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
反应种属	Cynomolgus,Human
偶联标记	Unconjugated

产品属性

抗体类型	Primary antibody
Format	Whole IgG
亚型	Human IgG1
轻链亚型	Kappa
SDS-PAGE	26.5 kDa (Light Chain) & 50.5 kDa (Heavy Chain), under reducing conditions; 176.7 kDa, under non-reducing conditions
纯化方法	Protein A purified
来源	CHO supernatant
物理外观	Liquid
储存缓冲液	Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	Lot by Lot
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	Store at -80℃ long term (18 months). Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS编号和信息	947687-13-0

数据库链接

IMGT/mAb-DB	295
Wikipedia	Ramucirumab
PubChem SID	178103962

靶标

Target ID

1813

名称

kinase insert domain receptor

缩写名

VEGFR-2

家族

Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family

别名

EBRT2

基因和蛋白信息

Species	Transmembrane Domains	Amino Acids	Chromosomal Location	Gene Symbol	Gene Name
Human	1	1356	4q12	KDR	kinase insert domain receptor
Mouse	1	1367	5 40.23 cM	Kdr	kinase insert domain protein receptor
Rat	1	1343	14p11	Kdr	kinase insert domain receptor

Ensembl Gene

ENSG00000128052 (Hs) , ENSMUSG00000062960 (Mm) , ENSRNOG00000046829 (Rn)

Entrez Gene

16542 (Mm) , 25589 (Rn) , 3791 (Hs)

OMIM

191306 (Hs)

Protein GI

11321597 (Hs) , 27777648 (Mm) , 6981128 (Rn)

UniProtKB

P35968 (Hs) , P35918 (Mm) , O08775 (Rn)

RefSeq Nucleotide

NM_002253 (Hs) , NM_010612 (Mm) , NM_013062 (Rn)

RefSeq Protein

NP_002244 (Hs) , NP_034742 (Mm) , NP_037194 (Rn)

Orphanet

229801 (Hs)

DrugBank Target

P35968 (Hs)

CATH/Gene3D

2.60.40.10 (N/A)

ChEMBL Target

CHEMBL3337 (Mm) , CHEMBL279 (Hs)

关联配体

Ligand ID	7390
名称	ramucirumab
别名	IMC-1121B
类别	Antibody
学名	4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide
生物活性评价	The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in ).
评价	Ramucirumab is an anti-VEGF2 receptor (KDR) monoclonal antibody that is used in oncology. Peptide sequences and structural information for ramucirumab are available from its IMGT/mAb-DB record.
单字母多肽序列
三字母多肽序列
翻译后修饰
化学修饰
临床描述	The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein. Participants will be randomized to ramucirumab or placebo in a 2:1 ratio (Main Global Cohort and China Maximized Extended Enrollment [ME2] Cohort). Participants may also receive ramucirumab if eligible to be enrolled in Open-Label Expansion (OLE) Cohort.
来源公司	Eli Lilly and Company

参考文献

1. Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z. (2002) Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy.. Int J Cancer, 97 (3): (393-9). [PMID:11774295]
2. Lu D, Shen J, Vil MD, Zhang H, Jimenez X, Bohlen P, Witte L, Zhu Z. (2003) Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.. J Biol Chem, 278 (44): (43496-507). [PMID:12917408]
3. Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY et al.. (2019) Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.. Lancet Oncol, 20 (2): (282-296). [PMID:30665869]